We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A study conducted in Israel, which has already vaccinated a large percentage of its population, has found that a single dose of Pfizer/BioNTech’s COVID-19 vaccine is highly effective at reducing infection, lending more support to the strategy of delaying second doses to increase initial vaccinations. Read More
Pfizer and BioNTech announced that they have dosed the first patients in a global study evaluating their COVID-19 vaccine in pregnant women 18 years and over. Read More
A U.S. appeals court judge this week issued an emergency stay of a December ruling by the U.S. International Trade Commission that the import, sale and marketing of a competitor to AbbVie ’s Botox wrinkle treatment, Jeuveau, must be stopped for nearly two years. Read More
Several U.S. states are pursuing their own versions of drug pricing policies introduced by the previous administration that would link the price of some prescription drugs to those in other “reference” countries. Read More
Eli Lilly has inked a global licensing deal with Rigel Pharmaceuticals for the company’s investigational anti-inflammatory drug, R552, in a pact worth potentially $960 million. Read More
A statistical analysis of multiple clinical trials that assessed Fujifilm’s antiviral Avigan (favipiravir) as a COVID-19 treatment has found that the drug showed limited efficacy in reducing mortality unless given early to infected patients. Read More
The U.S. should postpone second doses of the Pfizer/BioNTech COVID-19 vaccine in order to conserve supply and inoculate as many people as possible, two Canadian researchers recommended, citing data showing the initial dose to be highly effective. Read More